加州圣布鲁诺,Neuraltus制药公司(NeuraltusPharmaceuticals),一家致力于为神经退行性疾病开发创新疗法的私营生物制药公司,今日宣布:已经完成其试验性疗法NP001治疗肌萎缩侧索硬化(ALS,也被称为卢伽雷氏症)验证性2期研究最后一位患者的诊访工作。 这项研究(NCT02794857)在北美进行,目的是在系统性炎症升高的ALS患者中确认...
加州圣布鲁诺,Neuraltus制药公司(NeuraltusPharmaceuticals),一家致力于为神经退行性疾病开发创新疗法的私营生物制药公司,今日宣布:已经完成其试验性疗法NP001治疗肌萎缩侧索硬化(ALS,也被称为卢伽雷氏症)验证性2期研究最后一位患者的诊访工作。 这项研究(NCT02794857)在北美进行,目的是在系统性炎症升高的ALS患者中确认...
加州圣布鲁诺,Neuraltus制药公司(NeuraltusPharmaceuticals),一家致力于为神经退行性疾病开发创新疗法的私营生物制药公司,2018年1月15日宣布:已经完成其试验性疗法NP001治疗肌萎缩侧索硬化(ALS,也被称为卢伽雷氏症)验证性2期研究最后一位患者的诊访工作。 这项研究(NCT02794857)在北美进行,目的是在系统性炎症升高的AL...
NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study. Amyotroph Lateral Scler Frontotem- poral Degener. 2014; 15: 601-9.Miller RG, Zhang R, Block G, Katz J, Barohn R, Kasarskis E, Forshew D, Gopalakrishnan V, McGrath MS. NP001 regulation...
“We are thrilled to have submitted NP001 for FDA approval as the treatment platform may substantially preserve lung function … especially in patients identified through therapeutic biomarkers as having underlying, uncontrolled inflammation as a result of ALS,” Ari Azhir, PhD, founder and CEO of ...
转发微博【转发】@江南小蝶52:NP001-一种新型免疫调节剂的2期随机试验:ALS的安全性和早期疗效O网页链接罗伯特·G·米勒等人 神经神经免疫神经炎症. 2015.摘要目的:评估NP001(一种新型炎症单核细胞/巨噬细胞免疫...
Neuvivo today announced the publication of a peer-reviewed paper titled: "Macrophage Targeted Sodium Chlorite (NP001) Slows Progression of ALS through Regulation of Microbial Translocation".
Background/objective: Amyotrophic lateral sclerosis (ALS) is a diagnosis that incorporates a heterogeneous set of neurodegenerative processes into a single progressive and uniformly fatal disease making the development of a uniformly applicable therapeutic difficult. Recent multinational ALS natural history inc...
NP001 Treg细胞注射液,将在肌萎缩侧索硬化(ALS)、多系统萎缩(MSA)、阿尔茨海默病 (AD)患者中进行安全性和耐受性的开放、单臂、单中心临床研究。 本研究为全球首次应用鞘内注射的方式进行Treg临床研究,将通过本研究初步探讨NP001人体试验(FIH)鞘内注射的安全性与有效性剂量。
amyotrophic lateral sclerosis (ALS)C‐reactive protein (CRP)inflammationNP001respiratory functionIntroduction/Aims ALS is a heterogeneous disease that may be complicated or in part driven by inflammation. NP001, a regulator of macrophage activation, was associated with slowing disease progression in those...